Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or empirical data
PubMed 26929938 · doi:10.1967/s002449910335
What was done
This narrative review evaluated the clinical utility of fluorine-18-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) in assessing presynaptic dopaminergic function across Parkinson's disease, parkinsonian syndromes, essential tremor, and other movement disorders. The authors compared 18F-DOPA PET with single-photon emission computed tomography (SPET) using cocaine analogues, reviewed emerging radiopharmaceuticals, and discussed the diagnostic contributions of 18F-FDG PET and hybrid PET/magnetic resonance imaging (MRI).
What was found
The abstract provides no quantitative metrics, sensitivity/specificity values, or comparative diagnostic accuracy figures. The authors qualitatively concluded that 18F-DOPA PET remains a principal diagnostic tool for movement disorders, 18F-FDG PET aids in differentiating Parkinson's disease from other parkinsonian syndromes, and hybrid 18F-DOPA PET/MRI offers potential value for early diagnosis.
Why it matters
Differentiating Parkinson's disease from essential tremor and atypical parkinsonian syndromes is clinically important because only Parkinson's disease responds reliably to levodopa. Molecular neuroimaging targets specific presynaptic dopaminergic pathways before structural changes become detectable on conventional anatomical imaging.
Limits
This is a narrative review with no systematic search methodology, explicit inclusion criteria, or pooled quantitative data. The abstract reports no empirical sample sizes, diagnostic accuracy metrics, or comparative statistical evaluations.
Cited by
- supports Patients with essential tremor do not experience a loss of dopamine, and administering dopaminergic drugs to them worsens their tremors.